title: Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome.
abstract: Because women affected by polycystic ovary syndrome (PCOS) present an increased cardiovascular risk, the safety of estroprogestin treatment is debated and contrasting data have been reported. However, cardiovascular risk is not the same in all PCOS women and individual cardiovascular risk should be assessed before staring any estroprogestin treatment. The available data show that products containing both 2nd-generation and 3rd-generation progestins (including drospirenone and cyproterone acetate) represent a safe treatment in PCOS patients with regular cardiovascular risk. In PCOS patients with increased cardiovascular risk, a careful choice of estroprogestin product is needed and cardiovascular risk should be monitored during treatment. In obese PCOS patients with normal glucose tolerance and lipid profile, products containing 2nd-generation progestins may be preferred because of lower venous thromboembolism risk. In PCOS patients with altered lipid profile or glucose intolerance, 3rd-generation progestins should be used but, during treatment, cardiovascular risk should be periodically re-assessed. In special situations, metformin or statins may be added to estroprogestin treatment.
authors: DISMOT Department, University of Palermo, Palermo, Italy. carmina@unipa.it
authors: E
authors: E
authors: Carmina
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000627:therapeutic use; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy / Q000503:physiopathology*; D057285:Precision Medicine; D012306:Risk
chemical_list: D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal